At least 12 biotechs and pharmas are slated to report earnings this week. The Street expects 3Q12 EPS for Santarus Inc. (NASDAQ:SNTS) to jump tenfold on a 98% increase in revenues to $53 million. The company received U.S. rights to cholesterol lowering drug Fenoglide fenofibrate late last year from Shore Therapeutics Inc. EPS